Clinical trial
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic…
NCT00321724 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00321724 |
|---|---|
| Title | AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia |
| Official title | A Phase II Trial of AZD2171 in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia Patients |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia |
| Intervention type | Drug, Other |
| Interventions | cediranib maleate, laboratory biomarker analysis |
| Enrollment | 35 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2007 |
| First posted | May 4, 2006 |
| Last update posted | Jan 15, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: